Results 201 to 210 of about 8,919,237 (294)
Analysis of ESR1 mutations in plasma cell‐free DNA (cfDNA) is highly important for the selection of treatment in patients with breast cancer. Using multiplex‐ddPCR and identical blood draws, we investigated whether circulating tumor cells (CTCs) and cfDNA provide similar or complementary information for ESR1 mutations.
Stavroula Smilkou+11 more
wiley +1 more source
Geomatic Methods for the Analysis of Data in the Earth Sciences: Lecture Notes in Earth Sciences, Vol. 95 [PDF]
Nikolaos K. Pavlis
openalex +1 more source
Patient‐derived xenografts (PDXs) can be improved by implantation of a humanized niche. We tested different biomaterials and approaches, and demonstrate that the combination of an injectable biomaterial for scaffold creation plus an intravenous route for acute myeloid leukemia (AML) xenotransplantation provide the most convenient and robust approach to
Daniel Busa+13 more
wiley +1 more source
Separations Science Data Base: an abstractor's manual
Jack W. Roddy+2 more
openalex +2 more sources
The Future of Data Science [PDF]
Mukherjee, Sach, Richardson, Sylvia
openaire +4 more sources
Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer
This study employed targeted metabolomic profiling to identify 302 distinct metabolites present in platelet‐rich plasma (PRP), revealing aberrant metabolic profiles amongst individuals diagnosed with colorectal cancer (CRC). Compared to carcinoembryonic antigen (CEA) and cancer antigen 19‐9 (CA199), our metabolite panel showed improved sensitivity ...
Zuojian Hu+7 more
wiley +1 more source
Activity levels of Australians, June/July, 1985: User's guide for the machine-readable data file [PDF]
Social Science Data Archives
core
KMT2A degradation is observed in decitabine‐responsive acute lymphoblastic leukemia cells
We demonstrate that decitabine (DEC) not only degrades the DNA methyltransferase DNMT1 but also the leukemic driver lysine methyltransferase KMT2A likely due to structural similarity of the DNA‐binding CXXC domains. DEC influences KMT2A downstream processes and synergizes with menin inhibitor revumenib (REV) to decrease leukemic cell proliferation, and
Luisa Brock+10 more
wiley +1 more source